C-Reactive Protein (CRP)

This research aims to evaluate the effects of Hass Avocados on blood sugar control in adults with Type 2 diabetes. The study investigates whether eating Hass Avocados daily can reduce fasting blood sugar levels compared to consuming an equal calorie amount of other fruits. The trial is randomized and double-blind to carefully assess these effects under controlled conditions. Participants will be randomly assigned to one of two groups one group will consume one Hass Avocado daily about 240 calories per day, and the other group will receive other fruits matched for energy and form. This crossover design allows each participant to try both diets during the study period, helping to compare their impacts on blood sugar. During the study, participants will undergo blood tests at the start and after 5 weeks to measure fasting blood glucose, insulin, fructosamine, and glycated albumin levels. Researchers will monitor adherence to the diet and safety throughout the trial. The total participation spans at least 5 weeks per diet phase, with close monitoring of metabolic markers to understand how avocado consumption influences glycemic control.

This observational study focuses on patients with paroxysmal or persistent atrial fibrillation AF undergoing catheter ablation. The main aim is to explore how inflammation markers relate to local fat deposits, clinical risk factors, and changes after AF ablation. Researchers want to better understand the link between inflammation and heart tissue changes in this condition. The study involves collecting blood samples at various times to measure inflammation and fibrosis markers such as Interleukin 6, N-terminal propeptide of procollagen type 1 P1NP, chitinase-3-like protein 1 YKL-40, tumor necrosis factor TNF-alpha, GlycA, proprotein convertase subtilisinkexin type 9, and omega-3 fatty acids. These markers are analyzed to assess changes before and after the ablation procedure. Participants will be monitored over one year to evaluate reductions in inflammation and improvements in clinical outcomes including arrhythmia recurrence. The study includes clinical evaluations, blood tests for biomarkers, and electroanatomical mapping to assess atrial fibrosis. The research team will track how inflammation levels correspond with heart tissue changes and patient recovery during this period.

Researchers are evaluating whether the medicine colchicine can help reduce inflammation and lower the chance of developing an irregular heartbeat called atrial fibrillation after coronary artery bypass surgery CABG. This study focuses on adults scheduled for CABG and aims to provide initial data on colchicines effects on inflammatory markers and atrial fibrillation rates. It is a Phase 4, randomized, placebo-controlled trial that will help inform a larger future study. Participants will be randomly assigned to one of two groups one group receives colchicine capsules plus usual care, while the other receives placebo capsules plus usual care. Study medication is started 5 days before surgery and continued for 10 days after surgery or until hospital discharge, whichever comes first. Dosing depends on body weight and kidney function. Neither participants nor study staff will know which treatment is given. Blood samples and health information will be collected at multiple time points before and after surgery. Throughout the study, participants will have samples taken before surgery then at 24, 48, 72, and 96 hours after surgery and again at 10 days post-surgery or at discharge. Researchers will measure changes in inflammatory markers, monitor for atrial fibrillation up to 15 days post-operation, and track any side effects or changes in liver and kidney function. The study involves regular monitoring during the hospital stay to gather safety and effect size information over about two weeks.

Researchers are evaluating how C-reactive protein CRP levels and patient information leaflets PILs influence antibiotic prescribing in adults with acute respiratory symptoms in primary care settings in Kyrgyzstan. The study aims to assess the effectiveness and safety of three CRP thresholds 20, 40, 60 mgL and the impact of PILs on reducing unnecessary antibiotic use while ensuring patient safety. This multicentre, randomized controlled trial addresses antimicrobial resistance challenges by testing diagnostic and educational approaches in both rural and urban healthcare centres. All participants will receive CRP point-of-care testing using the Aidian QuickRead Go device during their consultation. They will be assigned to one of six groups based on CRP threshold levels and whether they receive a patient information leaflet explaining when antibiotics are unnecessary. The trial includes two main interventions the CRP POCT to guide antibiotic prescribing and PILs to educate patients. Follow-up calls will be conducted on days 3, 7, 14, and 21 to monitor health status and any adverse events. Participants aged 18 to 70 with symptoms like cough, shortness of breath, sore throat, stuffy nose, or wheezing lasting less than two weeks will be involved. They will provide informed consent and be assessed during routine consultations. The study will measure antibiotic use and hospitalisation rates over 21 days, ensuring safety through a dedicated review board. Data on symptoms, antibiotic use, and adverse events will be collected, with ongoing monitoring and statistical analyses planned to evaluate outcomes and subgroup effects.

Researchers are investigating the effects of selective C-reactive protein CRP apheresis in patients who have experienced an acute ST-elevation myocardial infarction STEMI. The study aims to assess whether reducing CRP levels with the PentraSorb4-CRP system, in addition to standard care, can decrease the size of the heart muscle damage caused by the infarction. This trial is a prospective, randomized, open-label study with masked outcome assessors, designed to provide evidence on the impact of this approach on infarct size and clinical outcomes after primary percutaneous coronary intervention PCI. Participants will be randomly assigned to receive either selective CRP apheresis using the PentraSorb4-CRP system as an add-on to standard treatment or standard care alone. The apheresis procedure will be performed on days 1, 2, and 3 following PCI. This trial compares these two groups to evaluate the effect of CRP removal on heart muscle injury and recovery. During the study, participants will undergo assessments including cardiac magnetic resonance imaging CMR at baseline, 4 months, and 12 months after PCI to measure heart function, infarct size, and other cardiac parameters. Various biomarkers related to myocardial injury, inflammation, and cardiac autonomic function will be monitored during hospitalization and follow-up. Safety and clinical outcomes such as mortality and heart failure-related hospitalizations will be tracked up to 12 months after randomization. The primary outcome is measured approximately 5 days after PCI, with extended follow-up to capture longer-term effects.

Researchers are studying patients with Philadelphia chromosome-negative Myeloproliferative Neoplasms MPN Ph negative to observe inflammatory biomarkers and track their changes over the course of the disease. The study aims to find links between these biomarkers and important disease outcomes such as blood clots, bleeding events, and progression to more severe disease stages like accelerated or blast phases. This observational study is designed to improve risk assessment for patients with these blood disorders. This study is observational and does not involve experimental treatments. It gathers data on inflammatory markers and clinical events in patients diagnosed with types of MPN including polycythemia vera, essential thrombocythemia, primary myelofibrosis, and post-PV or post-ET myelofibrosis. The study collects information retrospectively and prospectively from medical records and laboratory tests over a period of up to 60 months 5 years. Participants will be monitored through routine blood counts with white cell formulas to calculate inflammatory ratios, along with tracking arterial and venous thrombotic events. The study also measures conventional and new inflammatory biomarkers, time to thrombo-hemorrhagic events, survival status, and disease progression to fibrotic, accelerated, or leukemic phases. The total observation period is planned for 60 months, and participants provide informed consent to share their data for this research.

This research aims to evaluate the feasibility of a 2-week dietary intervention involving a daily whole food plant-based smoothie for patients scheduled for elective revision total knee arthroplasty TKA surgery. The study compares two groups one that consumes the smoothie daily before surgery and a control group that makes no dietary changes. Researchers want to assess compliance, barriers, satisfaction, and effects on inflammation, gut microbiome, postoperative pain, and opioid use. Participants are randomly assigned to either consume the smoothie daily for 14 days before surgery using a guide from the American College of Lifestyle Medicine or to maintain their usual diet without changes. The smoothie includes whole and high-fiber foods following a 6-step preparation guide. The control group receives no dietary intervention prior to their TKA revision surgery. During the study, participants are monitored for smoothie compliance, inflammatory markers IL-6 and CRP at various postoperative days and six weeks after surgery, gut microbiome changes via fecal samples, pain levels using numeric rating scales, and opioid use. Additional assessments include diet quantification, body composition measurements, range of motion, and frailty. The study tracks satisfaction with the diet and behavioral changes up to six months post-operation, with all assessments conducted at specified time points before and after surgery.

Postoperative delirium POD is a common complication in elderly patients after surgery, especially following hip fracture, vascular, or cardiac procedures. It is linked to longer hospital stays, cognitive decline, functional loss, and increased mortality within 6 to 12 months. This research evaluates whether a new measurement called the CRP-Albumin-Lymphocyte CALLY Index can predict the risk of POD in older adults undergoing hip fracture surgery. The study includes patients aged 65 and older having surgery for femoral neck or intertrochanteric fractures. Researchers will collect demographic information, medical history, and preoperative lab values to calculate the CALLY Index. Delirium presence will be assessed twice daily for three days after surgery using the DSM-5 criteria. Data on anesthesia, surgery details, postoperative complications, and hospital stay will also be recorded. Participants will be monitored for delirium starting in the post-anesthesia recovery unit and continuing during their hospital stay. Assessments include twice-daily delirium checks for three days and recording of outcomes such as intensive care unit stay length, overall hospital stay, and mortality. The main outcome measured is postoperative delirium as diagnosed by DSM-5 criteria. The study is observational and will last until the end of 2025.

Observational and animal studies suggest that certain non-nutritive sweeteners NNS, like sucralose and aspartame, may affect blood sugar control, especially in middle-aged and older adults with prediabetes. This research aims to understand how these sweeteners impact glucose regulation and to explore possible inflammatory mechanisms involved. The study focuses on establishing proof-of-concept for changes in glucose homeostasis after consuming sucralose compared to aspartame and a no-sweetener diet in adults aged 40 and over with prediabetes. After a 2-week diet to stabilize eating habits, 30 participants will be randomly assigned to one of three groups for six weeks a sucralose group, an aspartame group, or a control group with no NNS. All groups will follow diets matched in macronutrients and calories to avoid weight changes. The sweetener doses are set at 25% of acceptable daily intake levels for a 60 kg adult. The controlled feeding study ensures all participants consume the provided foods and sweeteners as assigned. Participants will be monitored using continuous glucose monitors to track 24-hour blood sugar control, and oral glucose tolerance tests will assess insulin sensitivity and beta cell function before and after the 6-week treatment. Inflammatory markers such as serum endotoxin, C-reactive protein, tumor necrosis factor alpha, interleukin 6, and monocyte chemoattractant protein-1 will also be measured. The study will last about eight weeks including the lead-in diet, and safety and adherence will be closely observed throughout.

Researchers are evaluating how increasing pulse consumption affects cardiometabolic risk factors in adults who currently eat less than 1.5 cups of pulses per week. This study compares two different pulse intake levels1.5 cups and 3 cups per weekagainst standard nutrition education based on the USDAs MyPlate guidelines. The primary focus is on changes in LDL cholesterol, C-reactive protein, HbA1c, and blood pressure, with additional interest in lipid profiles, diet quality, and life satisfaction measures. Participants are randomly assigned to one of three groups a control group receiving general healthy eating education, a group receiving 1.5 cup-equivalents of pulses weekly along with targeted nutrition education, and a group receiving 3 cup-equivalents of pulses weekly with similar education. All groups attend biweekly cooking classes and food demonstrations over 12 to 14 weeks. Pulse doses are tailored to individual calorie needs and provided for participants to prepare and consume at home. Participants in pulse groups also complete weekly consumption logs. Throughout the study, participants undergo baseline and week-12 visits involving fasting blood draws to measure cardiometabolic biomarkers, blood pressure assessments under standardized conditions, and completion of questionnaires on diet and life satisfaction. Dietary intake is assessed using detailed 3-day food records at both timepoints. Physical activity is also monitored. Researchers track adverse events and medication changes. The study duration accommodates scheduling challenges by allowing intervention periods from 12 to 14 weeks.